BLUEBIRD BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.9034 USD | +0.87% |
|
-6.52% | -34.54% |
Presenter SpeechJason Gerberry (Analysts)We're going to get going here, I think last presenter...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. Its lead gene therapy programs for sickle cell disease, B-thalassemia, and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. It has two gene therapies: ZYNTEGLO (betibeglogene autotemcel) and SKYSONA (elivaldogene autotemcel). ZYNTEGLO is the first gene therapy for people with B-thalassemia who require regular red blood cell transfusions. SKYSONA (elivaldogene autotemcel), also known as eli-cel, is used to slow the progression of eurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). It is also developing (lovotibeglogene autotemcel), also known as lovo-cel, as a one-time treatment for patients with sickle cell disease (SCD).
Calendar
2024-06-12
- Goldman Sachs Global Healthcare Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
HOLD
Number of Analysts
13
Last Close Price
0.9034
USD
Average target price
3.795
USD
Spread / Average Target
+320.03%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -34.54% | 174M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- BLUE Stock
- News bluebird bio, Inc.
- Transcript : Bluebird bio, Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 10
